Sponsor: COG
Sponsor Study ID: AALL1732
Study Title: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High Risk B ALL; Risk Adapted Post Induction Therapy for High Risk B ALL, Mixed Phenotype Acute Leukemia, and Disseminated B LLy
CTO #: 103328
NCT Number: NCT03959085
Phase: III
Protocol Type: Treatment
Age Group: Both
Disease Sites: Lymphoid Leukemia
Study Objectives: The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL).